



## Overview: Global Access Scorecard

Roivant Social Ventures (RSV) has designed a proprietary Global Access Scorecard that underwrites and directs our investment approach. The Scorecard includes the three criteria we identify as most relevant in evaluating whether the technology we are investigating for a potential investment or partnership has ability to bring greater access to medical care and healthcare to underserved global communities: (1) Target outcomes and target equity of the company and its technology (2) Scientific viability of the product (3) Corporate governance and business structure.

The Global Access Scorecard uses building blocks of existing Environmental, Social, Governance (ESG) principles and applies them to the biotech, healthcare, and drug manufacturing context. It analyzes net benefit to all stakeholders, including the patient/consumer, company employees, and company investors.

### GLOBAL ACCESS SCORECARD BREAKDOWN

#### Target Outcomes and Target Equity: 50% Weighting

- Identify how a product will improve access to medical care and to medicines for people in low- and middle-income countries. The technology we evaluate needs to rank high in this category to ensure RSV is aligned with the entrepreneur's long-term vision for the business. We breakdown this down into:
  - i. Patient needs
    - Define the target population for this technology. Is this population severely underserved and could this technology change the disparity in health equity here?
    - Size of the population: while not a determinant of whether RSV pursues a technology, we do consider the size of the impacted population for any technology
  - ii. Geographical boundaries
    - How broadly across the world can this technology be applied and if the technology is applicable only in a specific region or community, can it be deeply valuable so that it would fundamentally alter how this community accesses medical care?
  - iii. Improvements to baseline
    - If this product gets to market, how significantly would we expect it to change today's recognized healthcare disparities in its target population?

#### Scientific Product Viability: 30% Weighting

- Evaluate existing data for scientific efficacy or technological ingenuity. Understand competition in the market or in development
- Downstream Value Generation: Will this product be financially viable?

#### Governance and Corporate Structure: 20% Weighting

- (i) Leadership team and Board of Directors scientific and technical expertise
- (ii) Diversity of the C-suite and Board of Directors

# Global Access Scorecard

MAJOR CATEGORY	SUBCATEGORY
<p><b>Target Outcomes and Equity</b> (50% Weighting)</p>	<p>Patient Needs Geographical Boundaries Projected Improvements to Baseline</p>
<p><b>Viability of the Science</b> (30% Weighting)</p>	<p>Preclinical Data Downstream Value Generation Competition in the Market</p>
<p><b>Governance and Corporate Structure</b> (20% Weighting)</p>	<p>Expertise Diversity</p>

# Global Access Scorecard

MAJOR CATEGORIES	SUBCATEGORY	CRITERIA
<b>Target Outcomes and Equity</b> (50% Weighting)	Patient Needs	Target consumer/patient population is underserved Size of target consumer/patient base served is significant
	Geographical Boundaries	Either significant breadth of geographical reach or significant depth within a targeted underserved geographical region Local infrastructure needs support and investment to achieve better healthcare access
	Projected Improvements to Baseline	Product will meaningfully improve health equity within 5 years from market launch
<b>Viability of the Science</b> (30% Weighting)	Preclinical Data	How much does existing data support product viability
	Downstream Value Generation	Net Present Value Estimate
	Competition in the market	Net Present Value, Comparisons analysis and similar products available
<b>Governance and Corporate Structure</b> (20% Weighting)	Expertise in healthcare access	C-suite Board of Directors and Advisory Board
	Diversity	% People of Color % Women